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ORIGINAL ARTICLE
Nucleotide excision repair is a potential therapeutic target in
multiple myeloma
R Szalat1, MK Samur2, M Fulciniti1, M Lopez1, P Nanjappa3, A Cleynen2,4, K Wen1, S Kumar1, T Perini5, AS Calkins6, E Reznichenko6,
D Chauhan1, Y-T Tai1, MA Shammas3, KC Anderson1, J-P Fermand7, B Arnulf7,8, H Avet-Loiseau9, J-B Lazaro6 and NC Munshi1,3
Despite the development of novel drugs, alkylating agents remain an important component of therapy in multiple myeloma (MM).
DNA repair processes contribute towards sensitivity to alkylating agents and therefore we here evaluate the role of nucleotide
excision repair (NER), which is involved in the removal of bulky adducts and DNA crosslinks in MM. We ﬁrst evaluated NER activity
using a novel functional assay and observed a heterogeneous NER efﬁciency in MM cell lines and patient samples. Using next-
generation sequencing data, we identiﬁed that expression of the canonical NER gene, excision repair cross-complementation group
3 (ERCC3), signiﬁcantly impacted the outcome in newly diagnosed MM patients treated with alkylating agents. Next, using small
RNA interference, stable knockdown and overexpression, and small-molecule inhibitors targeting xeroderma pigmentosum
complementation group B (XPB), the DNA helicase encoded by ERCC3, we demonstrate that NER inhibition signiﬁcantly increases
sensitivity and overcomes resistance to alkylating agents in MM. Moreover, inhibiting XPB leads to the dual inhibition of NER and
transcription and is particularly efﬁcient in myeloma cells. Altogether, we show that NER impacts alkylating agents sensitivity in
myeloma cells and identify ERCC3 as a potential therapeutic target in MM.
Leukemia (2018) 32, 111–119; doi:10.1038/leu.2017.182
INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy with different
cytogenetic subgroups and variable patient outcomes.1 Despite
recent development of new drugs, including proteasome inhibi-
tors, Imids and monoclonal antibodies, therapeutic strategies
using DNA-damaging agents including melphalan, either as a
consolidation regimen by autotransplantation or in combination
with other drugs, remain an important component of therapy.2
Efﬁcacy of these agents may be affected by DNA repair
mechanisms, which are often dysregulated in cancer.3
Melphalan is a bifunctional alkylating agent that generates
bulky monoadducts and interstrand crosslinks requiring complex
and coordinated biological responses such as base excision repair,
nucleotide excision repair (NER), Fanconi anemia pathway and
homologous recombination (HR).4–9 Melphalan resistance has
been linked with upregulation of membrane efﬂux proteins,
increased binding to glutathione, Fanconi anemia pathway,
increased intercrosslink repair and transcriptional activity.7,8,10–12
The NER pathway recognizes and removes a wide range of DNA
damages induced by ultraviolet (UV), tobacco, alkylating agents or
DNA crosslinks. Depending on the location of the DNA damage
two distinct NER pathways intervene. Global genome repair-NER
recognizes and removes damages through the whole genome,
whereas transcription-coupled repair-NER selectively acts from the
transcribed strand of active genes. After DNA-damage recognition
step, global genome repair or transcription-coupled repair
converge onto the same path to perform excision of the damaged
fragment and synthesis of a new DNA strand portion.13,14
Abnormalities in NER-related genes have been described in a
number of malignancies with potential impact on clinical
outcome. Recurrent mutations affecting NER have been recently
reported in urothelial, ovarian and breast cancer that confers
higher chemosensitivity to cisplatin.15–17
Although alkylating agents remain an important component of
myeloma therapy, despite the availability of novel agents, studies
regarding the inﬂuence of NER on MM have not been system-
atically investigated. Here, we have focused on this pathway in
MM and report that NER is active in MM and demonstrate that its
inhibition leads to increased sensitivity to alkylating agents. We
also identiﬁed that ERCC3, a major NER gene, impacts the outcome
of MM patients and can be speciﬁcally targeted.
MATERIALS AND METHODS
Cell culture and reagents
Human MM cell lines (MMCLs) MM.1S, MM.1R, KMS11, RPMI8226, DOX40,
LR5, NCIH929, IM-9, OPM2, U266, JJN3, MOLP8, KMS34, LP1, MR20, KMS18,
KMS26, KMS12BM and KMS12PE, and the human stromal cell line HS5 were
cultured in RPMI-1640 medium supplemented with complete medium
(10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin
and 2 mM L-glutamine) at 37 °C and 5% CO2. BJ1 cell line was
cultured in supplemented DMEM medium. Xeroderma pigmentosum
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complementation group B (XPB) cell line corresponds to B-lymphocyte cell
line featured by two xeroderma pigmentosum group B mutations obtained
from the Corriel Biorepository (referenced as GM21148). Mutations are a
substitution of C4T at nucleotide 1273 in exon 8 of the ERCC3 gene
(c.1273C4T) [Arg425Ter (R425X)] and a T4C change at nucleotide 296 in
exon 3 (c.296T4C) [Phe99Ser (F99S)]. KMS11-TKO cells that corresponds to
the KMS11 cell line featured by a knock-out of MMSETII were kindly
provided by Josh Lauring from the John Hopkins University, Baltimore.18
Reagents. Melphalan, bendamustine and PYR41 were purchased from
Sigma (St Louis, MO, USA), spironolactone and triptolide from Selleck
Chemicals LLC (Houston, TX, USA) and 4-hydroperoxycyclophosphamide
from Santa Cruz Biotechnology (Dallas, TX, USA). Melﬂufen was obtained
from Oncopeptides AB (Stockholm, Sweden).
NER repair assay
We measured NER using the DDB2 proteo-probe as described previously.19
Brieﬂy, MMCL cells and samples of primary myeloma cells were grown on
polylysine-coated glass coverslips, or wall-less 24-well glass slides (Electron
Microscopy Sciences, Hatﬁeld, PA, USA). When using multiwell glass slides,
cells were grown in 15 μl drops per well and evaporation was prevented by
covering the slide with a sealing ﬂuid (Curiox Biosystems Inc., San Carlos,
CA, USA). After overnight incubation, cells were irradiated with 15–20 J/m2
UV-C at 254 nm using a StrataLinker 2400 (Stratagene, Agilent Technol-
ogies, Santa Clara, CA, USA). The cells were ﬁxed intact or 5 and 120 min
after irradiation. The proteo-probe treatment was performed as described
by Dreze et al.19 To obtain hybridization of the DDB2 proteo-probe to the
damaged DNA, we applied the proteo-probe diluted in phosphate-
buffered saline-bovine serum albumin to the ﬁxed cells for 60 min at 37 °C.
After washing in phosphate-buffered saline, we labeled the hybridized
proteo-probe for 1 h at 37 °C with 5 mg/ml anti-HA antibody (Cell
Signaling Technology Inc., Danvers, MA, USA) diluted in phosphate-
buffered saline-bovine serum albumin. The proteo-probe–HA antibody
complex was labeled similarly with 6.67 mg/ml goat anti-mouse Alexa
Fluor488 (Life Technologies, Carlsbad, CA, USA). After washing, the
coverslips or slides were mounted in ﬂuorogel medium containing
4′,6-diamidino-2-phenylindole (DAPI; Electron Micoscopy Science).
Proteo-probe and DAPI staining were imaged using a × 20/0.45
plan-APOCHROMAT or a × 63/1.4 oil plan-APOCHROMAT objective on an
upright ﬂuorescent microscope (Imager M2, Zeiss, Germany) coupled with
an AxioCam MRM camera (Carl Zeiss Microscopy, LLC, Thornwood, NY,
USA). The platform was controlled by the Axiovision 4.8 Software (Zeiss,
Carl Zeiss Microscopy, LLC). We processed images using the CellProﬁler
Software (Broad Institute, Cambridge, MA, USA, www.cellproﬁler.org).20
DAPI staining was used to deﬁne the area of the nuclei, and the
ﬂuorescence signal intensity of the DDB2 proteo-probe was quantiﬁed for
each nucleus. A minimum of 100 nuclei per condition was analyzed in each
experiment. Data were analyzed with GraphPad Prism 6 (GraphPad
Software Inc., Jolla, CA, USA). In addition, we used anti (6-4) photoproducts
antibody (Cosmo Bio USA, Inc., Carlsbad, CA, USA) to conﬁrm our ﬁndings
as a supplemental method in transient knockdown and ﬁve primary
samples. Each patient sample was evaluated using a MMCL as a positive
control.
Cell viability assay
Cell viability was assessed using CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI, USA) in 96-well tissue culture plates after
24 h exposure to drugs. Cell lines were plated at 15 000 cells per well in
Figure 1. NER proﬁciency is heterogeneous in MM cell lines. (a) NER proﬁciency of 20 MM cell lines. We used an NER functional assay to
evaluate NER proﬁciency. Each grey bar corresponds to a different MMCLs and represents the DDB2 proteo-probe signal per cell 120 min after
exposure to UV-C. The intensity of the signal corresponding to the DNA damage was evaluated through ﬂuorescence microscopy. Pictures
were taken with the Axiovision 4.8 Software (Zeiss, Carl Zeiss Microscopy, LLC) × 63 magniﬁcation, and the images were processed using the
CellProﬁler Software.20 Data in this graph are normalized to the average value of the maximum intensity of DDB2 proteo-probe signal that was
observed 5 min after UV. A minimum of 100 nuclei per condition was evaluated for each cell line. The results are representative of at least two
independent experiments. At least 108 nuclei were analyzed in each experiment (range from 108 to 2815). p53 status refers to either
homozygous deletion or homozygous mutation (*). (b) Pictures of NER functional assay. This ﬁgure shows pictures of NER evaluation in two
myeloma cell lines (NCIH929 and KMS12PE). Cells were cultured on polylysine-coated coverslips overnight and then half of the cells were
irradiated with UV-C. Cells were next ﬁxed 5 and 120 min after UV exposure and without UV. The pictures illustrate NER heterogeneity,
showing that NCIH929 completely repairs after 2 h, whereas KMS12PE does not. DAPI staining was used to deﬁne the area of the nuclei, and
the ﬂuorescence signal intensity of the DDB2 proteo-probe was quantiﬁed for each nucleus. (c) t(4;14) MM cell lines are featured by rapid NER
phenotype. The graph represents the normalized level of UV-induced damages 120 min after exposure to UV in t(4;14) and non-t(4;14)
MMCLs. t(4;14) cell lines repaired signiﬁcantly faster UV-induced DNA damages. Statistical analysis was performed with a Student’s t-test.
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triplicates for each dose of melphalan, melﬂufen, bendamustine, 4-
hydroperoxycyclophosphamide or triptolide. The GraphPad Prism 6
Software was used to plot curve ﬁts, to perform statistical analyses and
to establish half-maximal inhibitory concentration (IC50) values. For
combination studies, spironolactone (10 μM) or triptolide (10 nM) was
added 15 to 30 min before the alkylating agent.
Cell proliferation and apoptosis assay. MM cell proliferation was measured
using [3H]thymidine (Perkin-Elmer, Boston, MA, USA) incorporation assay as
described previously. Apoptosis was evaluated by ﬂow cytometric analysis
following Annexin-V staining.
Western blotting
Soluble cell lysates, chromatin fractions or immunoprecipitated protein
samples were heated at 70 °C for 10 min with NuPAGE sample loading
buffer. Proteins separated by electrophoresis on a NuPAGE Bis-Tris 4–12%
gradient gel (Novex) were transferred to a 0.45 μm pore nitrocellulose
membrane (Bio-Rad, Hercules, CA, USA). For immunoblotting, we used the
following primary antibodies: rabbit anti-XPB (1:1000; Santa Cruz
Biotechnology), anti-xeroderma pigmentosum complementation group C
(XPC; 1/1000; Cell Signaling Technology Inc.) and anti-GAPDH (1:1000; Cell
Signaling Technology Inc.). Goat anti-rabbit secondary antibodies con-
jugated to horseradish peroxidase were used at 1:5000 (Cell Signaling
Technology Inc.). All antibodies were diluted in phosphate-buffered saline-
0.05% Tween. Visualization was performed with a LAS-4000 Luminescent
Image Analyzer using SuperSignal West Pico Reagent (Thermo Fisher
Scientiﬁc Waltham, MA, USA).
NER gene expression proﬁle and OS in MM
We established a list of 70 genes involved in NER based on the
KEGG, Reactome, mSigdb database and from the literature
(Supplementary Table 1). We have performed differential gene expression
analysis for each NER gene between normal plasma cells and newly
diagnosed MM samples, and we also analyzed copy-number abnormalities
by using samples from the IFM-DFCI 2009 trial. Data were generated by
RNA-sequencing and CytoScan HD Array (Affymetrix, Santa Clara, CA, USA).
Methods for RNA-sequencing were described elsewhere.21 We used RNA-
sequencing data for MMCLs from Dr Jonathan Keats’ laboratory (http://
www.keatslab.org/).
We analyzed NER gene expression proﬁles and correlate it with overall
survival (OS) using Cox regression and log-rank test, in the IFM-DFCI 2009
(RNA-sequencing data set) data set and the IFM 2005-01 data set
(Affymetrix (Sacremento, CA, USA) Exon ST 1.0 Array, GSE39754). The
IFM-DFCI 2009 data set includes 16 normal patients and 292 newly
diagnosed MM patients treated with RVD (lenalidomide, bortezomib,
dexamethasone) with or without autologous stem cell transplant. All the
samples were used for gene expression and copy number proﬁling while
only samples from patients treated with high dose melphalan and auto-
transplant were considered for OS evaluation. The IFM 2005-01 data set
includes 170 newly diagnosed patients treated with VAD (vincristine,
adriamycine, dexamethasone) as induction therapy followed by auto-
logous stem cell transplantation after high-dose melphalan.
Patient samples
MM samples and healthy peripheral blood mononuclear cells were
obtained after informed consent was provided, in accordance with the
Declaration of Helsinki and under the auspices of a Dana-Farber Cancer
Institute Institutional Review Board approved protocol. Primary CD138+
plasma cells were puriﬁed from bone marrow aspirates using anti-CD138
microbeads as described previously (Miltenyi Biotech, Auburn, CA, USA).
Figure 2. NER pathway is dysregulated in MM. (a) Multiple NER-related genes are dysregulated in MM. The Circos plot represents the variation
of copy number and the expression level of 70 NER-related genes in a cohort of 292 newly diagnosed patients in comparison with 16 samples
from normal plasma cells, based on RNA-sequencing and CytoScan Array data. Each dot corresponds to one NER gene. The outer circle
represents gene expression level, green dots represent signiﬁcantly higher expressed genes, purple dots to signiﬁcantly lower expressed
genes and gray dots to genes with no differential expression. The inner circle represents copy-number abnormalities. Red dots correspond to
NER genes with ampliﬁcations, green dots are related to genes featured by deletions and gray dots relate to NER genes with no copy-number
abnormalities. (b) XPC is overexpressed in context of ampliﬁcation in MM. The right panel graph represents the correlation between XPC
expression and XPC ampliﬁcation in the same cohort. The left panel ﬁgure represents the level of expression of XPC in 292 myeloma patients
(MM) in comparison with 16 normal plasma cells from healthy donors (N). MM patients signiﬁcantly overexpress XPC (adj. P-value= 1× 10^5).
(c) ERCC3 expression signiﬁcantly impact OS in MM treated with alkylating agents. We evaluated the impact of ERCC3 expression level in MM
patients in two different data sets (IFM-DFCI 2009 and IFM 2005-01). We observed that high ERCC3 expression is signiﬁcantly associated with
poor outcome and shorter OS in MM. The ﬁgure represents Kaplan–Meier curbs based on ERCC3 median expression level.
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Small interfering RNA interference
We used ERCC3 and XPC small interfering RNA (siRNA) (s4796, s14929;
Invitrogen, Life Technologies, Carlsbad, CA, USA) following the manufac-
turer’s instructions. Non-targeting scrambled negative control siRNA
(AM4611; Invitrogen, Life Technologies) was used as a negative control.
RPMI8226 and LR5 cells were transiently transfected with 2 μM of ERCC3,
XPC and scrambled siRNA by electroporation using the AMAXA
Technology (Lonza Cologne AG, Cologne, Germany).
Lentiviral-mediated stable gene knockdown. Hairpin-containing PLKO.1
plasmids were obtained from Sigma Mission (Sigma-Aldrich Corp. St Louis,
MO, USA). Packaged viral particles were used to infect MM cells using
polybrene media (ﬁnal concentration 8 μg/ml). Infected MM cells were
selected by puromycin (0.5 μg/ml) (Sigma) for 72 h, and then left to
recover. Knockdown efﬁcacy was determined by western blotting and cells
were used for functional studies as described above.
Lentiviral-mediated gene overexpression. LentiORF clone of human ERCC3-
GFP-tagged (clone ID: PLOHS_100006334, cat. no. OHS5899) and lentiORF
turbo RFP control (cat. no. OHS5833) were purchased from GE Healthcare
Dharmacon (Lafayette, CO, USA). MM cells were transduced in polybrene
media (ﬁnal concentration 8 μg/ml) for 8 h. Infected cells were selected by
puromycin for 72 h and left to recover before the functional studies.
Transcription assay. RNA labeling by 5-ethynyl uridine (5-EU) incorpora-
tion was evaluated using the Click-iT RNA Imaging Kit (Invitrogen)
following the manufacturer's protocol. 5-EU signal and DAPI staining were
imaged using the imaging platform described above. We processed
images using the CellProﬁler Software.20 DAPI staining was used to deﬁne
the area of the nuclei, and the ﬂuorescence signal intensity of 5-EU was
quantiﬁed for each nucleus.
HR assay. We used ﬂuorescence-based HR assay substrate (pDRGFP;
Addgene, Cambridge, MA, USA).22 Brieﬂy, FLO-1 cells stably transfected
with HR substrate (Addgene) were transfected with a plasmid expressing
I-Sce I enzyme. The cells were then treated with scrambled siRNA and with
SiERCC3 for 72 h, and subsequently evaluated for confocal microscopy. HR
was assessed from the ﬂuorescence intensity of each microscopic ﬁeld
divided by the total number of cells in the corresponding ﬁeld. Average
background ﬂuorescence per cells, determined from untransfected cells,
were subtracted from values of transfected cells.
RESULTS
NER activity is heterogeneous in MM
We evaluated NER activity in 20 MM cell lines with different
cytogenetic and p53 background using the novel in vitro assay
developed and previously validated by us.19 We evaluated the NER
Figure 3. Speciﬁc knockdown of NER-related genes increases sensitivity to melphalan in MMCLs. (a and b) ERCC3 and XPC knockdowns impair
NER and increase sensitivity to melphalan. The ﬁgure represents the impact of XPC and ERCC3 knockdown on NER (left graph) and on
melphalan sensitivity (right graph) in RPMI8226 and LR5 cell lines. Three independent experiments were processed 72 h after transfection
with scrambled siRNA or siRNA targeting ERCC3 or XPC. The impact of knockdown on NER was evaluated with the measurement of remaining
(6-4) photoproducts signal 120 min after UV-C exposure, using anti-(6-4) photoproducts antibody. Cell viability was evaluated by CellTiter-Glo
(Promega Corporation, Madison, WI, USA). (c and d) Knockdown efﬁciency. Western blot evaluation of XPB and XPC levels 72 h after
transfection with scrambled or speciﬁc siRNA. (e and f) Stable knockdown of ERCC3 increases sensitivity to melphalan. The ﬁgure represents
the impact of ERCC3-stable knockdown in MM1S cell line on melphalan sensitivity. Cell viability was assessed by CellTiter-Glo 1 month after
knockdown and puromycin selection. Conﬁrmation of XPB knockdown was assessed by western blot. (g–i) Stable overexpression of ERCC3
increases resistance to melphalan. Apoptotic and cell death were assessed in MM1S and RPMI8226 cells transduced with either control (RFP-
GFP-positive cells) or ERCC3-GFP particles (GFP-positive cells) by ﬂow cytometric analysis following Annexin-V and propidium iodide (PI)
staining after exposure to melphalan at several doses. The percentage of live cells corresponds to the proportion of lives cells on the total of
GFP- or RFP-positive cells. Conﬁrmation of XPB overexpression was assessed by western blot.
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efﬁciency by measuring the extent of unrepaired (6-4) photo-
products after UV exposure in MM cell lines. Although all cell lines
eventually repaired495% of UV-induced DNA damage over time
(between 2 and 4 h after UV exposure: Supplementary Figure 1),
we observed heterogeneity in the ability of myeloma cell lines
to repair UV-induced DNA damage after 2 h as seen in Figure 1a
and b. The difference in ability to repair was not inﬂuenced by p53
deletion or other cytogenetic characteristics, except for the t(4;14)
translocation, which was consistently and signiﬁcantly associated
with a more rapid NER phenotype (Figure 1c). To get further
insight and to explain these observed differences in NER activity,
we evaluated the mutational proﬁle and NER-related gene
expression proﬁle of 15 MMCLs included in our study. We
observed 9 different missense mutations in NER genes in 8 out of
15 cell lines (Supplementary Table 1); 5 mutations were associated
with a slower NER phenotype but no NER deﬁciency
(Supplementary Figure 1). Both MM1S and MM1R cells presented
mutations in the xeroderma pigmentosum complementation
group A (XPA) gene (mutation D70H), and MM1R was also
mutated in the ERCC6 gene (mutation L682I). No NER gene was
signiﬁcantly differentially expressed between t(4;14) and non
t(4;14) MMCL (Supplementary Figure 3).
Figure 4. NER inhibition with spironolactone increases melphalan sensitivity in MM cell lines. (a and b) Spironolactone (sp.) and triptolide
inhibit NER in myeloma cells. RPMI8226 cells were incubated with dimethyl sulfoxide (DMSO), spironolactone (10 μM) or triptolide (1 μM) for 6 h
before NER evaluation. The ﬁgure represents the persistence of DNA-damage signal 150 min after exposure to UV (AFU: arbitrary ﬂuorescent
unit). Figure 4a shows representative merged pictures of DAPI and DDB2 proteo-probe signal (b). (c and d) Spironolactone (sp.) and triptolide
increase sensitivity to alkylating agents. (c) The left ﬁgure represents the impact of spironolactone (10 μM) or triptolide (10 nM) on melphalan
(left graph) and melﬂufen IC50 (right side graph) in RPMI8226 and LR5 MMCL. (d) Sensitivity to melphalan was evaluated in a panel of 20 MM
cell lines in context of DMSO or spironolactone. Each dot represents the corresponding melphalan IC50 for a distinct MMCL, in combination
with DMSO or spironolactone. IC50 was evaluated by CellTiter-Glo. (e) Spironolactone (sp.) increases sensitivity to melphalan through NER
inhibition and ERCC3 downregulation. The ﬁgure represents the impact of spironolactone on melphalan sensitivity in GM21148-XPB cell line
(green dots), which harbors two mutations in ERCC3, as compared with 20 myeloma cell lines (gray dots). Cell viability was evaluated with
CellTiter-Glo. GM21148-XPB cells are not sensitized to melphalan combined with spironolactone. These results were conﬁrmed in three
independent experiments. (f and g) Spironolactone (sp.) exposure enhances time-dependant XPB degradation. This western blot shows the
impact of 10 μM spironolactone on XPB expression (f) in three MMCLs (JJN3, LP1, NCIH929) after overnight exposure, and over time in the
NCIH929 (g). (h and i) Triptolide inhibits transcription. After exposure to triptolide (1 μM), spironolactone (10 μM), actinomycin D (2 μM,
transcription inhibitor used as a positive control) or DMSO for 6 h, the global RNA synthesis was evaluated by the measurement of 5-EU
incorporation. The ﬁgure shows representative merged pictures of DAPI and 5-EU signal. The intensity of the signal was evaluated through
ﬂuorescence microscopy (h) and quantiﬁed with the CellProﬁler Software. Triptolide but not spironolactone inhibits global transcription.
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Identiﬁcation of NER genes as potential therapeutic targets
To ﬁnd potential new therapeutic targets related to the NER
pathway, we analyzed our RNA-sequencing and SNP array
proﬁling data from primary myeloma samples from 292 MM
patients and 16 healthy donors and identiﬁed differentially
expressed NER genes and NER genes impacting OS. We observed
that 34 NER-related genes are differentially expressed between
MM cells and normal plasma cells and 23 genes are affected by
copy-number alterations (ampliﬁcation in 19 and deletion in 4)
(Figure 2 and Supplementary Table 2). For OS analysis, we used
two independent data sets (IFM 2005-01 and IFM-DFCI 2009).
We identiﬁed in both data sets that high ERCC3 expression
signiﬁcantly impacts OS (Figure 2), suggesting its potential as a
therapeutic target. ERCC3 expression was the only NER gene that
negatively impacts OS in both data sets. In addition, in a
multivariate analysis, we found that ERCC3 expression is an
independent prognosis factor (Supplementary Table 3).
We also investigated public whole-exome sequencing data
from a large cohort of MM patients to identify a recurrent
mutation in speciﬁc NER-related genes. Although no recurrent
mutation was identiﬁed, sporadic mutations in different NER
genes were found raising the possibility of involvement of the
common pathway (Supplementary Table 4).23,24
NER contributes to alkylating agent sensitivity in MM cells
As NER is involved in alkylating agent-induced DNA-damage
repair, we evaluated the role of NER on alkylating agent sensitivity
in MM. We evaluated the sensitivity to melphalan in our panel of
MM cell lines and we observed that ﬁve cell lines with the highest
IC50 for melphalan were also featured by a rapid NER activity
(Supplementary Figure 2).
To conﬁrm the speciﬁc impact of NER inhibition on alkylating
agents’ sensitivity, we next evaluated the impact of knockdown of
two NER-related genes, ERCC3 (gene coding for XPB), which we
identiﬁed as an independent prognosis marker in MM, and
xeroderma pigmentosum, complementation group C (XPC), which
is signiﬁcantly overexpressed in myeloma in context of ampliﬁca-
tion (Figure 2 and Supplementary Table 2). As seen in Figure 3,
ERCC3 and XPC knockdown inhibits NER and signiﬁcantly
increases sensitivity to melphalan in both cell lines RPMI8226
and LR5. Similarly, signiﬁcant increase in melphalan sensitivity was
observed using two shRNA-mediated knockdown targeting ERCC3
in the MM1S cell line (Figures 3e and f). Conversely, ERCC3-stable
overexpression in MM1S and RPMI8226 decreased sensitivity to
melphalan (Figures 3g–i).
Small-molecule NER inhibitors increase sensitivity to melphalan
We next evaluated the feasibility of targeting NER using small
molecules in myeloma cells. In particular, we evaluated two drugs
that target XPB. We evaluated the effect of spironolactone, a
recently described NER inhibitor,25 and triptolide26 on NER and
sensitivity to alkylating agents in MM cell lines (Figure 4 and
Supplementary Figure 4). We conﬁrmed that both spironolactone
and triptolide completely inhibit NER in MM cell lines. Importantly,
while the two drugs are targeting XPB, a key component of NER
and of the transcription initiation factor (TFIIH) complex, only
triptolide inhibits transcription (Figures 4h and i). This difference is
related to the distinct mechanisms of action of the two drugs.
Spironolactone acts through XPB degradation mediated by the E1
ubiquitin ligase in a time-dependent manner, whereas triptolide
inhibits the ATPase activity of XPB (Figures 4f and g and
Supplementary Figure 4D).25,27 Next, we treated MM cells with
spironolactone or triptolide in combination with alkylating agents.
We ﬁrst evaluated the combination of the two drugs in the model
of sensitive and resistant MM cell lines that has been established
with the RPMI8226 cell lines. In these MMCLs, the combination
signiﬁcantly increases sensitivity (RPMI8226) and overcomes
resistance (LR5) to melphalan and increases sensitivity to
melﬂufen (Figure 4d), bendamustine and cyclophosphamide
(Supplementary Figure 4). We conﬁrmed this result in our panel
of 20 MM cell lines. All cell lines were featured by a signiﬁcant
increased sensitivity to melphalan in combination with spirono-
lactone with a mean decrease in IC50 of 50.4% (range 14–79%).
Importantly, spironolactone does not impact melphalan sensitivity
in the XPB-GM-21148 cell line, which harbors ERCC3 mutations
and is NER deﬁcient, strongly suggesting that the impact of
spironolactone on alkylating agent sensitivity is mediated through
NER (Table 1 and Figures 1a and 4e).
In addition, we evaluated the efﬁcacy of spironolactone in the
presence of stromal cells, using either the HS5 cell line or human
stromal cells derived from a newly diagnosed myeloma patient. In
both conditions, we observed an increased sensitivity to
melphalan in the two MMCL RPMI8226 and MM1S cells,
reinforcing the potential therapeutic role of NER inhibition in
myeloma (Supplementary Figure 5).
NER can be monitored and targeted in MM patients
To conﬁrm our ﬁndings in primary myeloma cells, we evaluated 12
patient MM samples (eight relapsed/refractory and four newly
diagnosed patients). We found that NER was similarly active and
heterogeneous (Figure 5a), conﬁrming variability in NER proﬁ-
ciency in primary MM cells. We also conﬁrmed that spironolactone
inhibits NER in primary samples (Figures 5b and c). We observed a
signiﬁcant increased sensitivity to melphalan when used in
combination with either spironolactone (n= 7) or triptolide
(n= 4). Spironolactone increases sensitivity to melphalan in all
seven primary MM samples (Figures 5d and e) but not in healthy
peripheral blood mononuclear circulating cells (PBMCs). Similarly,
Table 1. Multiple myeloma cell line characterisitics (cytogenetic, IC50
melphalan and NER proﬁciency)
Cell line Cytogenetic TP53
status
Melphalan
IC50 (μM)
Melphalan
+sp. IC50 (μM)
% of IC50
decrease
LR5 t(14;16) HD 107.5 31.92 67.34
LP1 t(4;14) HD 91.03 79.12 18.93
DOX40 t(14;16) HD 63.74 20.99 60.52
MR20 t(14;16) HD 59.52 15.45 63.38
KMS12BM t(11;14) HD 56.07 13.78 75.79
GM21148 ERCC3
mutant
53.66 56.99 -
U266 t(11;14) HD 50.96 32.63 34.87
KMS34 t(4;14) HD 44.61 39.64 23.06
KMS18 t(4;14) 42.91 9.23 78.93
RPMI8226 t(14;16) HD 41.42 14.48 69.2
MM1R t(14;16) WT 41.08 16.88 43.48
IM-9 34.96 23.95 30.52
KMS12PE t(11;14) HD 34.53 25.02 40.24
JJN3 t(14;16) HD 32.33 12.93 65.89
OPM2 t(4;14) HD 30.21 7.6 76.01
MOLP8 t(11;14) 23.37 16.51 40.03
KMS11-
TKO
t(4;14)
MMSETII
KO
HD 22.56 8.76 61.17
KMS26 t(4;14) HD 21.95 5.81 72.05
MM1S t(14;16) WT 17.91 12.59 14.12
KMS11 t(4;14) HD 17.72 10.31 42.59
NCIH929 t(4;14) WT 12.39 10.31 30.65
Abbreviations: HD, homozygous deletion or homozygous mutation; IC50,
half-maximal inhibitory concentration; NER, nucleotide excision repair; sp.,
spironolactone; WT, wild type.
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triptolide signiﬁcantly increased the sensitivity to melphalan in
myeloma cells but not in healthy PBMCs. In addition, triptolide as a
single agent showed a strong activity in primary myeloma cells as
compared with normal PBMCs (Figure 5f), probably due to the
dual inhibition of both NER and transcription.
DISCUSSION
The advent of new therapies has provided major improvement in
OS in MM. However, alkylating agent-based therapies, especially
high-dose melphalan with stem cell transplant, remain an
important component of MM therapeutics.28,29 DNA damage
response (DDR) pathways have an important role in modulating
chemosensitivity to DNA-damaging agents in MM.30–33 NER, one
of the important DDR pathway, has been shown to remove
monoadducts generated by melphalan,5,34 but paradoxically, its
role in melphalan sensitivity has not been evaluated in contrast
with other mechanisms in MM cells.7,8,10,11
Removal of adducts generated by alkylating agents requires
NER. In this study, we evaluate the capacity of myeloma cells to
perform NER by measuring the removal of UV-induced (6-4)
photoproducts DNA lesions. We show an important role of NER in
MM and have observed heterogeneity in NER completion in a
panel of MMCL and a subset of primary samples (Figures 1 and 5).
In this study, we observed that all t(4;14) cell lines tested (eight)
share a rapid NER as compared with other MMCLs (Figure 1),
Figure 5. ERCC3 is a therapeutic target in MM. (a) NER proﬁciency in primary MM samples. CD138-positive cells from MM patients’ bone
marrow were puriﬁed with anti-CD138 microbeads, cultured overnight and exposed to UV-C. Each bar represents the normalized remaining
DNA-damage percentage 2 h after UV-C exposure for each sample. A control MMCL was processed as a positive control for each experiment
with primary samples. A minimum of 107 nuclei was analyzed in each experiment (range from 107 to 7390 nuclei). Similar to MM cell lines,
primary samples are featured by a heterogeneous NER efﬁciency. Eight samples from newly diagnosed (white bars) and four samples from
relapse/refractory myeloma patients (gray bars) were evaluated. Cytogenetic information was available for all except one sample. Sample MM6
is featured by the t(4;14) translocation, whereas other samples have a standard cytogenetic risk. Eight samples were evaluated with the DDB2
proteo-probe and four samples with the (6-4) photoproducts antibody. (b and c) Spironolactone inhibits NER in primary myeloma cells.
Primary myeloma cells were incubated with dimethyl sulfoxide (DMSO), or spironolactone (10 μM) overnight before NER evaluation. The ﬁgure
represents the persistence of DNA-damage signal 120 min after exposure to UV (AFU: arbitrary ﬂuorescent unit). The pictures show the
persistence of high DNA-damage signal in the presence of spironolactone conﬁrming NER inhibition. (d and e) Spironolactone and triptolide
increase sensitivity to alkylating agents in primary MM cells but not in healthy PBMCs. The ﬁgure represents the impact of spironolactone
(10 μM) or triptolide (10 nM) on melphalan in 7 (3 newly diagnosed and 4 relapse/refractory) and 4 primary MM samples (3 newly diagnosed
and 1 relapse/refractory) and in 5 and 4 healthy PBMCs, respectively. Each dot represents a distinct MM or PBMC sample. Viability was
evaluated by CellTiter-Glo. The ﬁgure shows the signiﬁcant increased sensitivity to melphalan (25 μM) in primary MM cells (d), whereas no
signiﬁcant increase was observed in PBMCs. Spironolactone itself impacts the viability of both MM cells and PBMCs but does not signiﬁcantly
increase melphalan sensitivity in healthy PBMCs. (Sp.= spironolactone; mel=melphalan). (f) Triptolide has signiﬁcant antimyeloma activity as
a single agent. Triptolide antimyeloma activity was evaluated in three PBMCs (blue line), four primary myeloma samples (red line) and three
MM cell lines (green line). Cells were cultured with different doses of triptolide (0–250 nM) for 24 h and cell viability was measured with
CellTiter-Glo. The ﬁgure shows that myeloma cells are more sensitive than PBMCs to triptolide.
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suggesting that in t(4;14) cells the ability to repair may contribute
to relative resistance to alkylating agents and the reported poor
prognosis in these patients.35,36 However, these ﬁndings do not
seem to be speciﬁc to the presence of t(4;14). Indeed, non-t(4;14)
cell lines and non-t(4;14) primary MM samples harbored a rapid
NER phenotype while one primary sample harboring this
translocation did not complete NER at 2 h (sample MM6 in
Figure 5a). The TKO cells (featured by MMSETII KO) and the native
KMS11 cell line harbor a similar NER phenotype (Figure 1a), and
TKO and KO cells have no signiﬁcant variation in NER gene
expression proﬁle (data not shown from GSE57863).37 Further-
more, no signiﬁcant difference in NER-related gene expression
between the t(4;14) and non-t(4;14) cell lines tested was observed
(Supplementary Figure 3B).
These results may be explained by the important heterogeneity
existing within t(4;14) MM38 and by other mechanisms inﬂuencing
NER. Notably, 5 min after exposure to UV-C, the t(4;14) MM MMCL
showed lower levels of (6-4) photoproducts than the non-t(4;14)
MMCL (Supplementary Figure 2A). Moreover, less (6-4) photo-
products were detected in the t(4;14) MM cells ﬁxed in methanol
before irradiation. This suggests that NER phenotype is inﬂuenced
by epigenomic differences affecting chromatin conformation and
consequently UV-C’s accessibility to DNA (Supplementary
Figure 6).
The subtle regulation of NER activity may be clinically relevant
as a surrogate prognosis marker or to predict sensitivity to
alkylating agents and further prospective evaluation of NER
should be performed to address this question. A previous study
from our group, in a small cohort of myeloma patients, reported
that slower capability to repair DNA damage is associated with
higher sensitivity to melphalan.39
We next evaluated the role of NER on melphalan sensitivity in
MM cells. We observed that melphalan-sensitive and -resistant
MMCLs have a variable NER phenotype (Table 1), and cell lines
with high rate of NER tends to be resistant to melphalan, as
illustrated in Supplementary Figure 2. In particular, the LR5
melphalan-resistant cell line harbored a rapid repair phenotype as
compared with the parental RPMI8226 cell line, which exhibited a
slower repair (Figure 1 and Supplementary Figure 2). To conﬁrm
the role of NER in resistance to alkylating agent sensitivity, we
knocked down XPC and ERCC3. In both cases, we observed NER
deﬁciency and a signiﬁcant increase in sensitivity to melphalan
(Figure 3). We showed that ERCC3 overexpression increases
resistance to melphalan and also ruled out a potential impact of
ERCC3 knockdown on HR (Supplementary Figure 7).
Identiﬁcation of ERCC3/XPB expression as an independent
prognosis marker in myeloma in context of autotransplant
(Supplementary Table 3) led us to evaluate XPB as a therapeutic
target. Spironolactone, a recently described potent inhibitor of
NER,25 increased the capacity of melphalan, melﬂufen,40 bend-
amustine and cyclophosphamide in killing MM cells (Figures 4 and
5 and Supplementary Figure 4). Similar results were obtained in
the presence of stroma demonstrating that NER is involved in
resistance to alkylating agents and conﬁrming that its inhibition
can reverse acquired resistance in MM cells (Supplementary
Figure 5). Interestingly, alkylating agents in MM are already
combined with other therapies such as proteasome inhibitors. Our
functional NER assay revealed that bortezomib, which is known to
inhibit certain DNA-damage repair pathways41 and widely used in
MM, does not affect NER in MM cells (Supplementary Figure 8).
Hence, NER inhibition may be another adjunct target to be
considered in combination therapies.
Triptolide, which leads to the dual inhibition of NER and
transcription by targeting XPB, further points toward targeting
XPB in MM. As illustrated in Figure 5f, triptolide has signiﬁcant
efﬁcacy in primary myeloma samples as a single agent as well as
in combination with an alkylating agent. Previous studies have
reported triptolide as a potential therapeutic drug in
myeloma,42–44 but its speciﬁc mechanisms of action as reported
here were not investigated to our knowledge.
Altogether, our data show that the NER pathway components,
in particular XPB, are potential therapeutic targets in MM.
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